Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating ...
WEB5 days ago · Selected KEYTRUDA ® (pembrolizumab) Indications in the U.S. ... This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the ...
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 …
WEB7 hours ago · LiGeR-HN1, a phase 3 trial, will evaluate the safety and efficacy of petosemtamab in combination with pembrolizumab, compared to pembrolizumab in 1L PD-L1+ r/m HNSCC patients.
FDA Panel Votes for Limits on Some GI Cancer Immunotherapy
WEB7 hours ago · Late last week, a US Food and Drug Administration (FDA) panel met to discuss whether to limit the use of nivolumab (Opdivo) and pembrolizumab (Keytruda) in patients with unresectable or metastatic ...
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating …
WEB5 days ago · About KEYTRUDA® (pembrolizumab) injection, 100 mg KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect ...
Pembrolizumab improves outcomes in high-risk bladder cancer
WEBSep 16, 2024 · Researchers found that postsurgical treatment with pembrolizumab (Keytruda), which is approved by the Food and Drug Administration (FDA) for treating at least 18 different cancers, was superior compared with observation.
FDA approves neoadjuvant/ adjuvant pembrolizumab for …
WEBOn October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of...
FDA approves pembrolizumab with chemotherapy for endometrial …
WEBOn June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBNov 16, 2023 · Selected KEYTRUDA ® (pembrolizumab) Indications in the U.S. Gastric Cancer. KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
FDA approves pembrolizumab with chemotherapy for HER2 …
WEBOn November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of...
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung …
WEBJun 3, 2023 · Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major...
- Some results have been removed